Glycation of the complement regulatory protein CD59 is a novel biomarker for glucose handling in humans

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 6, 2014, Pages

  Ghosh, Pamela ^a   Vaidya, Anand ^a   Sahoo, Rupam ^a   Goldfine, Allison ^c   Herring, Neil ^b   Bry, Lynn ^b   Chorev, Michael ^a   Halperin, Jose A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b PARTNERS HEALTHCARE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DRUG DOSE INTENSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD59; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE TOLERANCE TEST; GLYCOSYLATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84902330770     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-4232     Document Type: Article

References (38)

1. Acosta J, Hettinga J, Fl ückiger R, Krumrei N, Goldfine A, Angarita L, Halperin J. Molecular basis for a link between complement and the vascular complications of diabetes. Proc Natl Acad Sci U S A. 2000;97:5450-5455.
2. Rosoklija GB, Dwork AJ, Younger DS, Karlikay a G, Latov N, Hays AP. Local activation of the complement system in endoneurial mi ,crovessels of diabetic neuropathy. Acta Neuropathol (Berl). 2000; 99:55-62.
3. Zhang J, Gerhardinger C, Lor enzi M. Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathy. Diabetes. 2002;51:3499-3504.
4. Flyvbjerg A. Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily. Nat Rev Endocrinol. 2010;6: 94-101.
5. Hansen TK, Forsblom C, Saraheimo M, e t al. Association between mannose-binding lectin, high-sensitivity C-reactive protein and the progression of diabetic nephropathy in type 1 diabetes. Diabetologia. 2010;53:1517-1524.
6. Hovind P, Hansen TK, Tarnow L, et al. Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes: an inception cohort study. Diabetes. 2005;54:1523-1527.
7. U esugi N, Sakata N, Nangaku M, et al. Possible mechanism for medial smooth muscle cell injury in diabetic nephropathy: glycoxidation-mediated local complement activation. Am J Kidney Dis. 2004;44:224-238.
8. Woroniecka KI, Park AS, Mohtat D, Thomas DB, Pullman JM, Susztak K. Transcriptome analysis of human diabetic kidney disease. Diabetes. 2011;60:2354-2369.
9. Acosta JA, Be nzaquen LR, Goldstein DJ, Tosteson MT, Halperin JA. The transient pore formed by homologous terminal complement complexes functions as a bidirectional route for the transport of autocrine and paracrine signals across human cell membranes. Mol Med. 1996;2:755-765.
10. Qin X,Goldfine A,Krumrei N,et al Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complicatio ns of human diabetes Diabetes. 2004 53 2653-2661.
11. Benzaquen LR, Nicholson-Weller A, Halperin JA. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived gr owth factor from endothelial cells. J Exp Med. 1994;179:985-992.
12. Meri S, Morgan BP, Davies A, et al. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology. 1990;71:1-9.
13. Hamilton KK, Ji Z, Rollins S, Stewart BH, Sims PJ. Regulatory control of the terminal complement p roteins at the surface of human endothelial cells: neutralization of a C5b-9 inhibitor by antibody to CD59. Blood. 1990;76:2572-2577.
14. Qin X, Krumrei N, Grubissich L, et al. Deficiency of the mouse complement regulatory protein mCd59b results in spontaneous hemolytic anemia with platelet activation and progressive male infertility. Immunity. 2003;18:217-227.
15. Wu G, Hu W, Shahsafaei A, e t al. Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex. Circ Res. 2009;104:550-558.
16. Nishimura J, Murakami Y, Kinoshita T. Paroxysmal nocturnal hemoglobinuria: An acquired genetic disease. Am J Hematol. 1999; 62:175-182.
17. Acosta J, Qin X, Halperin J. Complement and complement regulatory proteins as potential molecular targets for vascular diseases. Curr Pharm Des. 2004;10:203-211.
18. Landi AP, Wilson AB, Davies A, et al. Determination of CD59 protein in normal human serum by enzyme immunoassay, usin g octylglucoside detergent to release glycosyl-phosphatidylinositol-CD59 from lipid complex. Immunol Lett. 2003;90:209-213.
19. Cohen RM, Franco RS, Khera PK, et al. Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. Blood. 2008;112:4284-4291.
20. Ghosh P, Sahoo R, Vaidya A, et al. A specific and sensitive assay for blood levels of glycated CD59:Anovel biomarker for diabetes.AmJ Hematol. 2013;88:670-676.
21. Murphy S, C hurchill S, Bry L, et al. Instrumenting the health care enterprise for discovery research in the genomic era. Genome Res. 2009;19:1675-1681.
22. Mellbin LG, Bjerre M, Thiel S, Hansen TK. Complement activation and prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Diabetes Care. 2012; 35:911-917.
23. Hansen TK, Tarnow L, Thiel S, et al. Association between mannosebinding lectin and vascular complications in type 1 diabetes. Diabetes. 2004;53:1570-1576.
24. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world-A growing challenge.NEngl J Med. 2007;356:213-215.
25. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653.
26. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31:1473-1478.
27. Diabetes Control and Complications Trial (DCCT). Update. DCCT Research Group. Diabetes Care. 1990;13:427-433.
28. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [published erratum appears in Lancet. 1999; 14;35:602]. Lancet. 1998;352:837-853.
29. Kumar PR, Bhansali A, Ravikiran M, et al. Utility of glycated hemoglobin in diagnosing type 2 diabetes mellitus: a community-based study. J Clin Endocrinol Metab. 2010 ;95:2832-2835.
30. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2008;31:S55-S60.
31. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria Arch Intern Med. 2001 161 397-405.
32. Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose toleranc e and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med. 2007;24:137-144.
33. Singleton JR, Smith AG, Bromberg MB. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care. 2001;24:1448-1453.
34. Sourij H, Saely CH, Schmid F, et al. Post-challenge hyperglycaemia is strongly associated with future macrovascular events and total mortality in angiographied coronary patients. Eur Heart J. 2010; 31:1583-1590.
35. Sumner CJ, Sheth S, Griffin JW, Cornblath DR, Polydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology. 2003;60:108-111.
36. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999;22:920-924.
37. Lehto T, Morgan BP, Meri S. Binding of human and rat CD59 to the terminal complement complexes. Immunology. 1997;90:121-128.
38. Davies CS, Harris CL, Morgan BP. Glycation ofCD59impairs complement regulation on erythrocytes from diabetic subjects. Immunology. 2005;114:280-286.